On Tuesday, Eli Lilly And Co (LLY  ) launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. Eli Lilly also reduced the price of the 2.5 mg and 5 mg vials.

These new offerings are available exclusively through LillyDirect Self-Pay Pharmacy Solutions, which enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance.

Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to make Zepbound vials more affordable, including:

  • Lowering the price of the 2.5 mg dose to $349 per month.
  • Lowering the price of the 5 mg dose to $499 per month.
  • Launching the Zepbound Self Pay Journey Program, which reduces the price of the 7.5 mg ($599) and 10 mg ($699) doses to $499 per month at first fill and refills that occur within 45 days of prior delivery.
Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen (autoinjector).

The recommended maintenance dosages are 5 mg, 10 mg or 15 mg injected subcutaneously once weekly.

Those starting on Zepbound will take Zepbound 2.5 mg for four weeks before increasing their dosage to 5 mg.

Zepbound sales in the fourth quarter reached $1.91 billion, up from $175.8 million a year ago. Annual sales reached $4.93 billion.

In August 2024, Eli Lilly released vials containing low doses of its weight-loss drug Zepbound (tirzepatide). Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.

Price Action: LLY stock is up 1.6% at $896 during the premarket session at last check Tuesday.